OTTAWA, ONTARIO--(Marketwired - March 28, 2017) - CannaRoyalty Corp. (CSE:CRZ)(CSE:CRZ.CN)(OTCQB:CNNRF) ("CannaRoyalty" of the "Company") is pleased to announce that one of its investee companies Resolve Digital Health ("Resolve"), a medical cannabis delivery system company that develops proprietary smart technology, has completed a $5 million Series A financing round led by Canadian TSX-listed company and ACMPR Licensed Producer, Aphria Inc. (TSX:APH) together with participation by CannaRoyalty which will now own 27.2% of the existing shares of Resolve on a non-diluted basis, a holding with an implied value of approximately $7.1 million based on the financing price.
"We are breaking new ground with the strides taken over the last two years to completely rethink the medical cannabis experience with a patient-centric approach that is measurable and trackable at the heart of our strategy," said Rob Adelson, Founder and CEO of Resolve Digital Health. "The advancements made thus far would not have been possible without the support and collaboration from Marc and the team at CannaRoyalty, which are even stronger today with our new partner, Aphria."
From its initial investment in October 2015, CannaRoyalty saw the immediate opportunity in Resolve. Through multiple share acquisitions, including C$80,000 invested in this financing, CannaRoyalty has acquired a substantial ownership position in Resolve and provided seed capital and resources for the research and development of Resolve's unique medical device system, Breeze. Unlike many existing cannabis products, Breeze is unique in that it provides an accurate, metered, treatment solution with pre-packaged, single use pods filled with the highest quality cannabis buds or oil, making it easy and safe for end-users.
"We are thrilled about participating in the closing of this financing. It provides third party validation of our initial investment in Resolve at a significantly higher valuation," said Marc Lustig, CEO of CannaRoyalty. "It is an example of the success of our business model that includes identifying high-value cannabis assets, partnering through investment and assisting in the growth and commercialization of brands, products and devices - while increasing value for our shareholders."
CannaRoyalty is a fully integrated, active investor and operator in the legal cannabis sector. Our focus is to build and support a diversified portfolio of growth-ready assets in high-value segments of the cannabis sector, including research, consumer brands, devices and intellectual property. Our management team combines a hands-on understanding of the cannabis industry with seasoned financial know-how, assembling a platform of holdings via royalty agreements, equity interests, secured convertible debt and licensing agreements.
About Resolve Digital Health
Resolve Digital Health is the leading provider of standardized medical cannabis for patients suffering from cancer, arthritis, migraine headaches, chronic pain and other diseases. The company's proprietary technology and cloud-based health information platform found in Resolve's debut product Breeze addresses the numerous issues with currently available methods of cannabis delivery - establishing a standard of care and rigorous medical approach previously missing from the medical cannabis industry. With over two years of research and development, the complete product ecosystem will be initially available Spring 2017 in select dispensaries in the United States. For more information, visit www.resolvedigitalhealth.com.
Forward Looking Statements
When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward- looking statements. Forward-looking statements may include, without limitation, statements including the Company's expectations with respect to pursuing new opportunities and its future growth and other statements of fact.
Although CannaRoyalty has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US Federal Laws; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize.
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CannaRoyalty's periodic filings with Canadian securities regulators. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CannaRoyalty disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CannaRoyalty does not assume any liability for disclosure relating to any other company mentioned herein.